EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone

Rhett G Marchant iD, Samantha J Bryen, Melanie Bahlo, Anita Cairns, Katherine R Chao, Alastair Corbett, Mark R Davis, Vijay S Ganesh, Roula Ghaoui, Kristi J Jones, Andrew J Kornberg, Monkol Lek und 18 weitere

Annals of Clinical and Translational Neurology · 2024-05 · 11 (5) · 1250-1266

DOI: 10.1002/acn3.52041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 27.03.2024. Verfasst von Rhett G Marchant und 29 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Neuromuscular Diseases, Exome Sequencing. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHGRI NIH HHS, NEI NIH HHS, National Human Genome Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Most families with heritable neuromuscular disorders do not receive a molecular diagnosis. Here we evaluate diagnostic utility of exome, genome, RNA sequencing, and protein studies and provide evidence‐based recommendations for their integration into practice.

Methods

In total, 247 families with suspected monogenic neuromuscular disorders who remained without a genetic diagnosis after standard diagnostic investigations underwent research‐led massively parallel sequencing: neuromuscular disorder gene panel, exome, genome, and/or RNA sequencing to identify causal variants. Protein and RNA studies were also deployed when required.

Results

Integration of exome sequencing and auxiliary genome, RNA and/or protein studies identified causal or likely causal variants in 62% (152 out of 247) of families. Exome sequencing alone informed 55% (83 out of 152) of diagnoses, with remaining diagnoses (45%; 69 out of 152) requiring genome sequencing, RNA and/or protein studies to identify variants and/or support pathogenicity. Arrestingly, novel disease genes accounted for

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromuscular DiseasesExome SequencingHumansMaleFemaleAdultSequence Analysis, RNAChildAdolescentExomeMiddle AgedYoung AdultChild, PreschoolHigh-Throughput Nucleotide SequencingInfantGenetic Testing

Autor:innen und Institutionen

  • Faculty of Medicine and Health, The University of Sydney, Westmead, New South Wales, Australia.
  • Kids Neuroscience Centre, Kids Research, Children's Hospital at Westmead, Westmead, New South Wales, Australia.
  • Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Functional Neuromics, Children's Medical Research Institute, Westmead, New South Wales, Australia.
  • Population Health and Immunity, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
  • Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.

ORCID-Profile: Rhett G Marchant, Frances J Evesson, Leigh B Waddell, Sandra T Cooper

Förderung

  • NHGRI NIH HHS
  • NEI NIH HHS
  • National Human Genome Research Institute
  • National Health and Medical Research Council
  • National Eye Institute

Zitieren

APA

Marchant, R. G., Bryen, S. J., Bahlo, M., Cairns, A., Chao, K. R., Corbett, A., Davis, M. R., Ganesh, V. S., Ghaoui, R., Jones, K. J., Kornberg, A. J., Lek, M., Liang, C., MacArthur, D. G., Oates, E. C., O'Donnell-Luria, A., O'Grady, G. L., Osei-Owusu, I. A., Rafehi, H., …, & Cooper, S. T. (2024). Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone. Annals of Clinical and Translational Neurology, 11(5), 1250-1266. https://doi.org/10.1002/acn3.52041

Vancouver

Marchant RG, Bryen SJ, Bahlo M, Cairns A, Chao KR, Corbett A, et al. Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone. Annals of Clinical and Translational Neurology. 2024;11(5):1250-1266. doi:10.1002/acn3.52041

BibTeX
@article{Marchant2024,
  author = {Marchant, Rhett G and Bryen, Samantha J and Bahlo, Melanie and Cairns, Anita and Chao, Katherine R and Corbett, Alastair and Davis, Mark R and Ganesh, Vijay S and Ghaoui, Roula and Jones, Kristi J and Kornberg, Andrew J and Lek, Monkol and Liang, Christina and MacArthur, Daniel G and Oates, Emily C and O'Donnell-Luria, Anne and O'Grady, Gina L and Osei-Owusu, Ikeoluwa A and Rafehi, Haloom and Reddel, Stephen W and Roxburgh, Richard H and Ryan, Monique M and Sandaradura, Sarah A and Scott, Liam W and Valkanas, Elise and Weisburd, Ben and Young, Helen and Evesson, Frances J and Waddell, Leigh B and Cooper, Sandra T},
  title = {Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {5},
  pages = {1250--1266},
  doi = {10.1002/acn3.52041}
}
Kostenlos starten →